GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small ...

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within o ...

The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...

Commercials run by Hims & Hers advertise prescription injectable weight-loss drugs without disclosing safety and risk information.

The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease severity.

Age differences are seen in the efficacy of treatments for type 2 diabetes, according to study results published in the Journal of the AMA.

Allurion’s CEO confirmed to Medical Device Network that the company has changed advertising, patient follow-up, and physician ...

A network meta-analysis reveals age-dependent variations in efficacy of popular diabetes drugs, with SGLT2 inhibitors showing ...